S
Santhera Pharmaceuticals Holding AG
SIX:SANN
Santhera Pharmaceuticals Holding AG
SIX:SANN
Price:
9.35 CHF
0.11%
Market Closed
Updated:
May 17, 2024
Santhera Pharmaceuticals Holding AG
Cost of Revenue
|
Santhera Pharmaceuticals Holding AG
Cost of Revenue Peer Comparison
Comparables:
ADCT
ACIU
CRSP
BSLN
IDIA
Competitive Cost of Revenue Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Cost of Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
S
|
Santhera Pharmaceuticals Holding AG
SIX:SANN
|
Cost of Revenue
-CHf3.2m
|
CAGR 3-Years
32%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
Cost of Revenue
-$2.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
AC Immune SA
NASDAQ:ACIU
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Cost of Revenue
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Cost of Revenue
-CHf26.8m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Idorsia Ltd
SIX:IDIA
|
Cost of Revenue
-CHf6.3m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Santhera Pharmaceuticals Holding AG's Cost of Revenue?
Cost of Revenue
-3.2m
CHF
-3.2m
CHF
Based on the financial report for Dec 31, 2023, Santhera Pharmaceuticals Holding AG's Cost of Revenue amounts to -3.2m CHF.
What is Santhera Pharmaceuticals Holding AG's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
7%
7%
Over the last year, the Cost of Revenue growth was 10%. The average annual Cost of Revenue growth rates for Santhera Pharmaceuticals Holding AG have been 32% over the past three years , 7% over the past five years .
You don't have any saved screeners yet
